Atrial Fibrillation

  • sponsor
    Coherex Medical, Inc.
Updated on 3 December 2020
heart failure
vascular disease
warfarin therapy
transient ischemic attack
anticoagulation therapy


Prospective, multicenter, randomized, active control, clinical trial of the Coherex WaveCrest Left Atrial Appendage (LAA) device compared to the Watchman® LAA device for the reduction in risk of ischemic stroke or systemic embolism in subjects with non-valvular atrial fibrillation who have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation.

Condition Atrial Fibrillation, Atrial Fibrillation (Pediatric)
Clinical Study IdentifierTX133597
SponsorCoherex Medical, Inc.
Last Modified on3 December 2020


Yes No Not Sure

Inclusion Criteria

Documented evidence of paroxysmal, persistent, or permanent non-valvular atrial fibrillation
At least 18 years of age
Calculated CHADS2 score ≥ 2 or CHA2DS2-VASc score ≥ 3
Indication for warfarin therapy with an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation
Willing and able to comply with post-implant anticoagulation and antiplatelet regimen
Willing to participate in the required follow-up visits and tests
Subject has been informed of the nature of the trial, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) at the site

Exclusion Criteria

Atrial fibrillation (AF) due to a reversible cause (e.g. thyrotoxicosis or post-operative)
Known contraindication and/or allergy to warfarin, nickel, aspirin, intravenous contrast, or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel), which cannot be adequately pre-medicated or desensitized
Conditions other than atrial fibrillation requiring long-term anticoagulation therapy
Contraindications to percutaneous catheterization procedures
Prior surgical LAA occlusion/exclusion or implanted with LAA occlusion device, or any prior attempt of such procedures
Prior percutaneous or surgical closure of a patent foramen ovale or atrial septal defect
Inability or unwillingness to take oral anticoagulation for 45 days post-procedure
New York Heart Association Class IV heart failure
Prior cardiac transplant, history of mitral valve replacement, or transcatheter mitral valve intervention, or any mechanical valve implant
History of symptomatic carotid, intervertebral, or intracranial artery occlusion or stenosis without revascularization with the exception of known occlusion without symptoms > 6 months
Modified Rankin Scale Score ≥ 4
Chronic resting heart rate > 110 bpm
Congenital cardiac anomalies requiring cardiac surgery or interventional repair
Stroke or transient ischemic attack (confirmed by Neurologist) within 60 days prior to enrollment
Myocardial infarction within 60 days prior to enrollment
Sepsis or any infection requiring oral antibiotic therapy within 14 days or intravenous antibiotic therapy within 30 days prior to enrollment
Surgical or interventional cardiovascular and non-cardiovascular procedure including cardioversion within 30 days prior to enrollment or AF ablation within 60 days prior to enrollment or any planned general surgery or planned interventional procedure within 90 days after enrollment or any planned cardiac surgery
On renal replacement therapy, serum creatinine > 3.0 mg/dl (265 μmol/L) or calculated creatinine clearance < 25 ml/minute
Thrombocytopenia (<60,000 platelets/mm3), leucopenia (white blood cell count < 3,000 cells/mm³), or anemia (hemoglobin concentration < 10 gram/deciliter) based on blood work done within 30 days prior to enrollment
Any medical disorder or psychiatric illness that would interfere with successful completion of the trial
Currently participating in an investigational drug trial or another device trial that has not completed the primary endpoint (trials requiring extended follow-up for products that are commercially available are not considered investigational trials). Concurrent enrollment in the ACC LAAO Registry is permitted
Subject belongs to a vulnerable population (see definition in Appendix I: Acronyms and Definitions)
Any condition that would reduce life expectancy to less than 2 years
Women of childbearing potential who are, or plan to become pregnant during the time of the trial (method of assessment per physician discretion)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note